KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas

Journal of Clinical Neuroscience

Volumn 21, Issue 10, 2014, Pages 1719-1724

  Gousias, Konstantinos ^a   Niehusmann, Pitt ^a   Gielen, Gerrit ^a   Simon, Matthias ^a   Boström, Jan ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Department of Radiology   (Germany)

Author keywords

Anaplastic oligoastrocytomas; Chromosome region maintenance protein 1 exportin 1; IDH1 R132H mutation status; Karyopherin a2 importin 1

Indexed keywords

EXPORTIN 1; ISOCITRATE DEHYDROGENASE 1; KARYOPHERIN; KARYOPHERIN A2; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL RECEPTOR; EXPORTIN 1 PROTEIN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; KARYOPHERIN ALPHA; KARYOPHERIN ALPHA 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CELL NUCLEUS; CONTROLLED STUDY; CORRELATIONAL STUDY; CRM1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KPNA2 GENE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ASTROCYTOMA; BRAIN NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MUTATION; PROGNOSIS;

ADULT; AGED; ALPHA KARYOPHERINS; ASTROCYTOMA; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; KARYOPHERINS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETROSPECTIVE STUDIES;

EID: 84908556568     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.01.011     Document Type: Article

References (49)

1. Nuño M, Birch K, Mukherjee D, et al. Survival and prognostic factors of anaplastic gliomas. Neurosurgery 2013;73:458-65.
2. Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 2013;49:3477-85.
3. Central Brain Tumor Registry of the United States. Available from: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf. [accessed 20 August 2012].
4. Jiang H, Ren X, Cui X, et al. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol 2013;15:775-82.
5. Frenel JS, Leux C, Loussouarn D, et al. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neurooncol 2013;114:85-91.
6. Tortosa A, Viñolas N, Villà S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003;97:1063-71.
7. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110:156-62.
8. Liang BC, Thornton Jr AF, Sandler HM, et al. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991;75:559-63.
9. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18.
10. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56.
11. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337-43.
12. Shirai K, Suzuki Y, Okamoto M, et al. Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res 2010;51:589-94.
13. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487-93.
14. Miller CR, Dunham CP, Scheithauer BW, et al. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006;24:5419-26.
15. Park CK, Lee SH, Han JH, et al. Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer 2009;9:450.
16. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22.
17. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344-50.
18. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
19. Weller M, Berger H, Hartmann C, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 2007;13:6933-7.
20. Gousias K, Becker AJ, Simon M, et al. Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas. J Neurooncol 2012;109:545-53.
21. Shen A, Wang Y, Zhao Y, et al. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009;65:153-9 [discussion 159-60].
22. Zheng M, Tang L, Huang L, et al. Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 2010;116:884-91.
23. Dahl E, Kristiansen G, Gottlob K, et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin α2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 2006;12:3950-60.
24. van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin proteins, Crm1 and Karyopherin b1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009;124:1829-40.
25. Mortezavi A, Hermanns T, Seifert HH, et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2011;17:1111-21.
26. Wang CI, Wang CL, Wang CW, et al. Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Cancer 2011;128:2364-72.
27. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-82.
28. Noske A, Welchert W, Niesporek S, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008;112:1733-43.
29. Huang WY, Yue L, Qiu WS, et al. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009;32:E315.
30. Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009;21:229-35.
31. Forgues M, Difilippantonio MJ, Linke SP, et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 2003;23:5282-92.
32. Zannini L, Lecis D, Lisanti S, et al. Karyopherin-α2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem 2003;278:42346-51.
33. Tseng SF, Chang CY, Wu KJ, et al. Importin KPNA2 is required for proper nuclear localization and multiple functions of NSB1. J Biol Chem 2005;280:39594-600.
34. Chen YC, Su YN, Chou PC, et al. Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005;280:32505-11.
35. Noetzel E, Rose M, Bornemann J, et al. Nuclear transport receptor karyopherin-α2 promotes malignant breast cancer phenotypes in vitro. Oncogene 2012;31:2101-14.
36. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003;282:59-69.
37. Kau TR, Silver PA. Nuclear transport as a target for cell growth. Drug Discov Today 2003;8:78-85.
38. Yashiroda Y, Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003;10:741-8.
39. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012;83:1021-32.
40. Fornerod M, Ohno M, Yoshida M, et al. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997;90:1051-60.
41. Fukuda M, Asano S, Nakamura T, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997;390:308-11.
42. Hallberg E, Wozniak RW, Blobel G. An integral membrane protein of the pore membrane domain of the nuclear envelope contains a nucleoporin-like region. J Cell Biol 1993;122:513-21.
43. Mansfeld J, Güttinger S, Hawryluk-Gara LA, et al. The conserved transmembrane nucleoporin NDC1 is required for nuclear pore complex assembly in vertebrate cells. Mol Cell 2006;22:93-103.
44. Inoue H, Kauffman M, Shacham S, et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 2013;189:2317-26.
45. Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013;161:117-27.
46. Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012;3:137-51.
47. Teng SC, Wu KJ, Tseng SF, et al. Importin KPNA2, NSB1, DNA repair and tumorigenesis. J Mol Histol 2006;37:293-9.
48. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545-51.
49. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.